Skip to main content

People in the News: Aug 23, 2011


Enzo Biochem has added four executives to lead its Enzo Life Sciences subsidiary. The new team will focus on pharmaceutical and clinical applications.

Bruce Taillon has been named head of global technology business development. He previously worked in Roche 454 Life Sciences, where he was responsible for world-wide business development efforts centered on the company's next-generation sequencing platform and its potential use in diagnostic assays.

John D’Errico will lead Enzo Life Sciences' commercial merchandising operations. D’Errico joins Enzo from VWR Scientific, where he managed that company's life sciences product portfolio. Before that, he worked at Harvard Biosciences, where he headed business development efforts for the firm's Genomic Solutions business, which was later sold to Digilab.

Kara Cannon has been appointed head of global marketing. She joins Enzo from Pall Corp., where she held executive positions in the areas of diagnostics, biotechnology, and biosciences.

Paul Munger has been tapped to lead Enzo Life Sciences' global manufacturing operations. He previously held an executive position at Pierce Chemical, now a division of Thermo Fisher Scientific, as well as a senior manufacturing management role at Transgenomic, where he was responsible for scaling up drug intermediate candidates. Most recently, Munger led the US-based manufacturing of regulated diagnostic kits for Idexx Labs.

The Scan

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.